News for Charles River Laboratories Stock (CRL)

Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript

Seeking Alpha • Wednesday

Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall

Zacks Investment Research • Wednesday

Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research • Wednesday

Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates

Zacks Investment Research • Wednesday

Charles River Laboratories raises annual profit forecast on stabilizing biotech demand

Reuters • Wednesday

Charles River Laboratories Announces Third-Quarter 2024 Results

Business Wire • Wednesday

Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics

Zacks Investment Research • Monday

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research • 10/30/24

Why Charles River (CRL) is Poised to Beat Earnings Estimates Again

Zacks Investment Research • 10/29/24

CRL Gears Up for Q3 Earnings: Here's What You Need to Know

Zacks Investment Research • 10/22/24

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch

Zacks Investment Research • 10/18/24

Charles River Launches New Retrogenix® Non-Human Protein Library

Business Wire • 10/17/24

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Business Wire • 10/16/24

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica

Zacks Investment Research • 10/10/24

Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform

Business Wire • 10/08/24

Charles River Provides Translational Expertise at Neuroscience 2024

Business Wire • 10/03/24

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

Business Wire • 10/02/24

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Business Wire • 09/19/24

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

Zacks Investment Research • 09/18/24

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing

GlobeNewsWire • 09/18/24

Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

Business Wire • 09/17/24

CRL Stock May Benefit From New Neuroscience Research Collaboration

Zacks Investment Research • 09/09/24

Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?

Zacks Investment Research • 09/06/24

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Business Wire • 09/04/24

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Business Wire • 09/03/24